CD33 and acute myeloid leukemia: In their first-in-man clinical trial (NCT02944162), they tested the safety and efficacy of third generation CD33 directed CAR NK construct with CD28 and 4-1BB co-stimulatory domains using NK cells derived from NK-92 cell lines in 3 relapsed/refractory AML patients.